We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 19, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
USE OF MYELIN BASIC PROTEIN AS A NOVEL GENETIC FACTOR FOR RHEUMATOID ARTHRITIS
GENE TARGETING VECTOR, METHOD FOR MANUFACTURING SAME, AND METHOD FOR USING SAME
PRODUCTION METHOD FOR ARTIFICIAL CANCER STEM CELL AND INDUCED DIFFERENTIATION METHOD THEREFOR
NOVEL VITAMIN D RECEPTOR MODULATOR WITH PARTIAL AGONIST ACTIVITY
Reagents and Methods for PCR
Engineered CO2 fixing microorganisms producing carbon-based products of interest
E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
TECHNIQUE FOR CLEAVING OUT PART OF poly(A) CHAIN AND/OR 3'-TERMINAL SEQUENCE OF mRNA TO INHIBIT TRANSLATION REACTION